Cargando…

Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report

BACKGROUND: Crizotinib is recommended as first-line therapy in ROS1-driven lung adenocarcinoma. However, the optimal first-line therapy for this subgroup of lung cancer is controversial according to the available clinical data. CASE PRESENTATION: Here, we describe a 57-year-old man who was diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Liang, Xia, Jingwen, Zhang, Jing, Zhang, Yuanyuan, Zhu, Ning, Zhang, Peng, Zhang, Youzhi, Zhang, Xiujuan, Li, Shengqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781300/ https://www.ncbi.nlm.nih.gov/pubmed/29361925 http://dx.doi.org/10.1186/s12890-018-0585-9

Ejemplares similares

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
por: Zhang, Yongchang, et al.
Publicado: (2022)

The interaction of lncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells
por: Zhang, Xiao-Dan, et al.
Publicado: (2018)

EphrinA3 is a key regulator of malignant behaviors and a potential prognostic factor in lung adenocarcinoma
por: Yiminniyaze, Ruzetuoheti, et al.
Publicado: (2022)

High expression of EZR (ezrin) gene is correlated with the poor overall survival of breast cancer patients
por: Zhang, Rongju, et al.
Publicado: (2019)

TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR
por: Xie, An, et al.
Publicado: (2021)

Next Generation Sequencing Reveals a Synchronous Trilateral Lung Adenocarcinoma Case with Distinct Driver Alterations of EGFR 19 Deletion or EGFR 20 Insertion or EZR-ROS1 Fusion
por: Zhang, Xuhui, et al.
Publicado: (2020)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

EZR promotes pancreatic cancer proliferation and metastasis by activating FAK/AKT signaling pathway
por: Xu, Jian, et al.
Publicado: (2021)

Ipsilateral breast metastasis from lung adenocarcinoma harboring anaplastic lymphoma kinase or ROS1 rearrangement and significant response after targeted therapy: report of two cases
por: Zheng, Jing, et al.
Publicado: (2020)

EzrA Contributes to the Regulation of Cell Size in Staphylococcus aureus
por: Jorge, Ana M., et al.
Publicado: (2011)

Functional Domain Analysis of the Cell Division Inhibitor EzrA
por: Land, Adrian D., et al.
Publicado: (2014)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Protein tyrosine phosphatase PTPL1 suppresses lung cancer through Src/ERK/YAP1 signaling
por: Wang, Jing, et al.
Publicado: (2022)

Investigation of the freely available easy-to-use software ‘EZR' for medical statistics
por: Kanda, Y
Publicado: (2013)

Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell
por: Zhao, Jing, et al.
Publicado: (2016)

Multiple cerebral infarctions in ROS1‐rearranged lung adenocarcinoma
por: Ikushima, Hiroaki, et al.
Publicado: (2021)

Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCR
por: Wang, Jinghui, et al.
Publicado: (2014)

Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC/PKC-EZR (ezrin) pathway
por: Qureshi-Baig, Komal, et al.
Publicado: (2019)

EzrA: a spectrin-like scaffold in the bacterial cell division machinery
por: Cleverley, Robert, et al.
Publicado: (2015)

Silencing of lncRNA EZR-AS1 inhibits proliferation, invasion, and migration of colorectal cancer cells through blocking transforming growth factor β signaling
por: Liu, Zhenhua, et al.
Publicado: (2019)

Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement
por: Gao, Qiongqiong, et al.
Publicado: (2017)

Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features
por: Cao, Bing, et al.
Publicado: (2015)

Mxi1-0 Promotes Hypoxic Pulmonary Hypertension Via ERK/c-Myc-dependent Proliferation of Arterial Smooth Muscle Cells
por: Dong, Liang, et al.
Publicado: (2022)

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
por: Yue, Dongsheng, et al.
Publicado: (2021)

An elderly female patient with ROS1 rearrangement primary lung adenocarcinoma and breast carcinoma: a rare case report and review of the literature
por: Yang, Xiaojuan, et al.
Publicado: (2019)

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma
por: Lan, Shaowei, et al.
Publicado: (2020)

Hybrid Schwannoma-Perineurioma Frequently Harbors VGLL3 Rearrangement
por: Dickson, Brendan C., et al.
Publicado: (2021)

A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis
por: Takahara, Yutaka, et al.
Publicado: (2020)

Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report
por: Fang, Liying, et al.
Publicado: (2017)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review
por: Xu, Chun‐wei, et al.
Publicado: (2017)

Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report
por: Wang, Jinjing, et al.
Publicado: (2021)

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
por: Scheffler, Matthias, et al.
Publicado: (2015)

A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features
por: Zhou, Jianya, et al.
Publicado: (2016)

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
por: Joshua, Julie Mariam, et al.
Publicado: (2018)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Ogura, Hayato, et al.
Publicado: (2017)

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
por: Gao, Yuan, et al.
Publicado: (2017)

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
por: Tachi, Hiroaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ver1trg0dlrp4cc4f0ulif7ngs